- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06097403
Cardiovascular Complications in Children With COVID 19
Prevalance of Cardiovascular Complications in Children With COVID 19 in Assuit University Children Hospital
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In December 2019, coronavirus disease 2019 (COVID-19) was first described in Wuhan, China, in patients complaining of flulike symptoms.1 The virus was isolated and identified as a new strain of coronavirus, now named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2 ) . Cardiovascular complications of COVID-19 have received less medical attention; nevertheless, the first cases of myocarditis in COVID-19 patients have been reported,3, 4, 5, 6 and myocarditis has been recognized as the cause of death in some covid 19 patients.7 Pathology usually is focal within the myocardium, but there is a risk of arrhythmia as well as progression to fulminant heart failure and cardiogenic shock.
Clinical presentation of SARS-CoV-2 myocarditis varies among cases. Some patients may present with relatively mild symptoms, such as fatigue and dyspnea,4 , 5 whereas others report chest pain or chest tightness on exertion.3 , 6 Many patients do deteriorate, showing symptoms of tachycardia and acute-onset heart failure with cardiogenic shock.3, 4, 5 In these severe cases, patients may also present with signs of right-sided heart failure, including raised jugular venous pressure, peripheral edema, and right upper quadrant pain.10 The most emergent presentation is fulminant myocarditis, defined as ventricular dysfunction and heart failure within 2-3 weeks of contracting the virus.8 The early signs of fulminant myocarditis usually resemble those of sepsis: the patient often presents febrile with low pulse pressure, cold or mottled extremities, and sinus tachycardia.10 Myocarditis is an inflammatory disease of the heart characterized by inflammatory infiltrates and myocardial injury without an ischemic cause.8 The most commonly identifiable cause of myocarditis in the United States and other developed countries is viral.9 , Arrhythmia is recognized as one of the possible clinical manifestations of COVID-19 patients. One observational study of the clinical characteristics of COVID-19 patients in Hubei, China, reported a 7.3% incidence of heart palpitations among its 137 patients 13 Moreover, Wang et al reported that arrhythmia was a cause of intensive care unit transfer in 44.4% of COVID- Coagulation and inflammatory parameters are mildly altered in COVID-19 infection, whereas MIS-C is characterized by laboratory evidence of a proinflammatory and procoagulant state
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient less than 18 years old Presented with COVID 19
Exclusion Criteria:
- Not presented with covid19
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalance of cardiovascular complications in children with COVID 19
Time Frame: Baseline
|
estimate the prevalence of cardiovascular complications among pediatric patients with covid 19 in Isolation Unit , Chest unit , and Cardiology unit in Assiut University Children Hospital
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- cardiovascular complications
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID 19 Associated Coagulopathy
-
University of IowaCompleted
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Westlake UniversityShaoxing Central HospitalRecruitingCOVID 19 Associated CoagulopathyChina
-
Ain Shams UniversityCompletedCOVID 19 Associated CoagulopathyEgypt
-
Cantonal Hospital ZenicaCompletedSepsis | Septic Shock | Coagulation Disorder | COVID 19 Associated CoagulopathyBosnia and Herzegovina
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Theravance BiopharmaCompletedAcute Lung Injury (ALI) Associated With COVID-19 | Inflammatory Lung Conditions Associated With COVID-19United Kingdom
-
Theravance BiopharmaCompletedAcute Lung Injury (ALI) Associated With COVID-19 | Lung Inflammation Associated With COVID-19Moldova, Republic of, United Kingdom, United States, Brazil, Finland, Romania, Ukraine
-
University Hospital in KrakowCompletedMicrobial Colonization | Dysbiosis | COVID-19 Respiratory Infection | HAI | VAP - Ventilator Associated PneumoniaPoland
-
ProgenaBiomeRinati Skin, LLCWithdrawnCovid-19 | COVID | Corona Virus Infection | Sars-CoV2 | SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere | SARS Pneumonia | Coronavirus-19United States
Clinical Trials on Covid 19 swap
-
Aarhus University HospitalWithdrawnStroke, Acute | Seizure Disorder | Neurological Diseases or ConditionsDenmark
-
AstraZenecaCompleted
-
Hasanuddin UniversityChulalongkorn UniversityCompleted
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...CompletedCoronavirus InfectionFrance
-
Melike CengizCompleted
-
AstraZenecaCompleted
-
University of PennsylvaniaPublic Health Management CorporationCompleted
-
University of Texas at AustinUnknownFood InsecurityUnited States
-
University of PennsylvaniaPublic Health Management CorporationCompleted
-
Duke UniversityNorth Carolina Department of Health and Human ServicesCompleted